share_log

Altimmune | 8-K: Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Altimmune | 8-K: Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Altimmune | 8-K：Altimmune公布2024年第二季度财务业绩并提供业务最新情况
美股SEC公告 ·  08/08 07:09
Moomoo AI 已提取核心信息
On August 8, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2024. The company highlighted the progress of its lead candidate, pemvidutide, in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune presented promising data at medical conferences, showing pemvidutide's potential in weight loss and metabolic disease treatment. The company is preparing for an end-of-Phase 2 meeting with the FDA, expected in late Q3 2024, to discuss Phase 3 trial designs for obesity treatment. Financially, Altimmune reported $164.9 million in cash, cash equivalents, and short-term investments. Research and development expenses increased to $21.2 million, primarily due to pemvidutide development costs. General and administrative expenses rose to $5.6 million, attributed to increased stock compensation expenses. The company recorded a net loss of $24.6 million, or $0.35 per share, compared to a net loss of $16.1 million, or $0.32 per share, in the same period last year. The increase in net loss was primarily due to higher research and development spending.
On August 8, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2024. The company highlighted the progress of its lead candidate, pemvidutide, in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune presented promising data at medical conferences, showing pemvidutide's potential in weight loss and metabolic disease treatment. The company is preparing for an end-of-Phase 2 meeting with the FDA, expected in late Q3 2024, to discuss Phase 3 trial designs for obesity treatment. Financially, Altimmune reported $164.9 million in cash, cash equivalents, and short-term investments. Research and development expenses increased to $21.2 million, primarily due to pemvidutide development costs. General and administrative expenses rose to $5.6 million, attributed to increased stock compensation expenses. The company recorded a net loss of $24.6 million, or $0.35 per share, compared to a net loss of $16.1 million, or $0.32 per share, in the same period last year. The increase in net loss was primarily due to higher research and development spending.
2024年8月8日，临床阶段的生物制药公司altimmune报告了截至2024年6月30日第二季度的财务状况。该公司强调了其领先候选药物pemvidutide在治疗肥胖症和代谢失调相关的脂肪肝（MASH）领域的进展。Altimmune在医学会议上展示了有前途的数据，证明了pemvidutide在减少体重和治疗代谢疾病方面的潜力。该公司正在为与FDA举行2期结束会议做准备，预计在2024年第三季度末举行，以讨论肥胖症治疗的3期试验设计。在财务方面，Altimmune报告了16490万美元的现金、现金等价物及短期投资。研发费用增至2120万美元，主要是由于pemvidutide的研制成本。管理及一般性开支升至560万美元，归因于股票补偿费用增加。该公司录得净亏损2460万美元，每股亏损0.35美元，而去年同期的净亏损为1610万美元，每股亏损0.32美元。净亏损的增加主要归因于更高的研发支出。
2024年8月8日，临床阶段的生物制药公司altimmune报告了截至2024年6月30日第二季度的财务状况。该公司强调了其领先候选药物pemvidutide在治疗肥胖症和代谢失调相关的脂肪肝（MASH）领域的进展。Altimmune在医学会议上展示了有前途的数据，证明了pemvidutide在减少体重和治疗代谢疾病方面的潜力。该公司正在为与FDA举行2期结束会议做准备，预计在2024年第三季度末举行，以讨论肥胖症治疗的3期试验设计。在财务方面，Altimmune报告了16490万美元的现金、现金等价物及短期投资。研发费用增至2120万美元，主要是由于pemvidutide的研制成本。管理及一般性开支升至560万美元，归因于股票补偿费用增加。该公司录得净亏损2460万美元，每股亏损0.35美元，而去年同期的净亏损为1610万美元，每股亏损0.32美元。净亏损的增加主要归因于更高的研发支出。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息